A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer

International Journal of Oncology

Volumn 14, Issue 5, 1999, Pages 821-831

  Stehlin, John S ^a   Giovanella, Beppino C ^a   Natelson, Ethan A ^a   De Ipolyi, Peter D ^a   Coil, Doug ^a   Davis, B ^b   Wolk, D ^a   Wallace, P ^a   Trojacek, A ^a  

^a St Joseph's Medical Center Houston   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

9 nitrocamptothecin; Camptothecin; Chemotherapy; Pancreatic cancer

Indexed keywords

9-NITROCAMPTOTHECIN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CA 19-9 ANTIGEN; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; RUBITECAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PANCREAS TUMOR; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; QUALITY OF LIFE; RADIOGRAPHY; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CA-19-9 ANTIGEN; CAMPTOTHECIN; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PANCREATIC NEOPLASMS; PATIENT SELECTION; QUALITY OF LIFE; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 0033126463     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.14.5.821     Document Type: Article

References (27)

1. American Cancer Society. Cancer Facts and Figures, 1997.
2. Giovanella BC: Topoisomerase I inhibitors. In: Cancer Therapeutics: Experimental and Clinical Agents. Teicher BA (ed.) Humana Press, Inc., Totowa, NJ, pp137-152, 1997.
3. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT and Sim GA: Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88: 3888-3890, 1966.
4. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, et al: DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246: 1046-1048, 1989.
5. Giovanella BC, Hinz HR, Kozielski AJ, Stehlin JS Jr, Silber R and Potmesil M: Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res 51: 3052-3055, 1991.
6. Pantazis P, Hinz HR, Mendoza JT, Kozielski AJ, Williams LJ Jr, Stehlin JS Jr, et al: Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res 52: 3980-3987, 1992.
7. Pantazis P, Early JA, Kozielski AJ, Mendoza JT, Hinz HR and Giovanella BC: Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocamptothecin: differential response of nontumorigenic and tumorigenic human breast cells in vitro. Cancer Res 53: 1577-1582, 1993.
8. Pantazis P, Kozielski AJ, Mendoza JT, Early JA, Hinz HR and Giovanella BC: Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non-tumorigenic and tumorigenic cells in vitro. Int J Cancer 53: 863-871, 1993.
9. Natelson EA, Giovanella BC, Verschraegen CF, Fehir KM, De Ipolyi PD, Harris N, et al: Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents. Ann NY Acad Sci 803: 224-230, 1996.
10. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
11. Steinberg W: The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 85: 350-355, 1990.
12. Klein JP and Moeschberger ML: Survival analysis - techniques for truncated and censored data. Springer-Verlag, New York, 1997.
13. Schellens JHM, Creemers GJ, Beijnen JH, Rosing H, De Boer-Dennert M, McDonald M, et al: Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br J Cancer 73: 1268-1271, 1996.
14. Creemers JG, Gerrits CJH, Eckardt JR, Schellens JHM, Burris HA, Planting AST, et al: Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. J Clin Oncol 15: 1087-1093, 1997.
15. Zamboni WC, Stewart CF, Cheshire PJ, Richmond LB, Hanna SK, Luo X, et al: Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models. Clin Cancer Res 4: 743-753, 1998.
16. Rothenberg ML: New developments in chemotherapy for patients with advanced pancreatic cancer. Oncology 10 (Suppl 9): 18-22, 1996.
17. Kardinal CG and Cole JT: Chemotherapy of breast cancer. In: The Chemotherapy Source Book. Perry MC (ed.) 2nd edition. Williams & Wilkins, Baltimore, MD, pp1125-1183, 1996.
18. Physicians' Desk Reference. Medical Economics Co., Montvale, NJ, 1998.
19. Gerrits CJH, De Jonge MJA, Schellens JHM, Stoter G and Verweij J: Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Br J Cancer 76: 952-962, 1997.
20. Haskell CM, Lavey RS and Ramming KP: Exocrine pancreas. In: Cancer Treatment. Haskell CM (ed.) 4th edition. W.B. Saunders Company, Philadelphia, pp502-512, 1995.
21. Wittekind C and Hermanek P: UICC classification of pancreatic cancer. Int J Pancreatol 16: 99-120, 1994.
22. Freeny PC, Marks WM, Ryan JA and Traverso LW: Pancreatic ductal adenocarcinoma: diagnosis and staging with dynamic CT. Radiology 166: 125-133, 1988.
23. Fishman EK, Wyatt SH, Key DR, Kuhlman JE and Siegelman SS: Spiral CT of the pancreas with multiplanar display. AJR 159: 1209-1215, 1992.
24. Forsmark CE, Lambiase L and Vogel SB: Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA 19-9. Pancreas 9: 731-734, 1994.
25. Gattani AM, Mandeli J and Bruckner HW: Tumor markers in patients with pancreatic carcinoma. Cancer 78: 57-82, 1996.
26. Willett CG, Daly WJ and Warshaw AL: CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer. Am J Surg 172: 350-352, 1996.
27. Carmichael J, Fink U, Russell RCG, Spittle MF, Harris AL, Spiessi G and Blatter J: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73: 101-105, 1996.